<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023214</url>
  </required_header>
  <id_info>
    <org_study_id>STH15983</org_study_id>
    <nct_id>NCT04023214</nct_id>
  </id_info>
  <brief_title>The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease</brief_title>
  <official_title>Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will compare endothelial function in patients with ADPKD with matched&#xD;
      healthy volunteers and normotensive chronic kidney disease stage 1 &amp; 2 patients. Patients&#xD;
      will undergo a single assessment of endothelial function and measurement of plasma and urine&#xD;
      levels of biomarkers of endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following recruitment we will record the following baseline demographics; age, gender,&#xD;
      smoking status, body mass index, medical history.&#xD;
&#xD;
      Participants will undergo a noninvasive vascular assessment, venepuncture and will provide a&#xD;
      urine sample.This will be done during a single visit to the CRF.&#xD;
&#xD;
      Noninvasive vascular assessment will consist of:&#xD;
&#xD;
        1. Peripheral Arterial Tonometry This will be measured using the EndoPAT system (Itamar&#xD;
           Medical)&#xD;
&#xD;
           Endothelial shear stress flow stimulus will be provided by inflation of a blood pressure&#xD;
           cuff around the upper non-dominant arm to suprasystolic pressure (but &lt;300mmHg) for 5&#xD;
           minutes. Following release of the cuff the resulting digital microcirculation&#xD;
           vasodilatory response to ischaemic hyperaemia, quantified as the pulse wave amplitude,&#xD;
           will be monitored over 5 minutes. The peak pulse wave amplitude measured at 90-150s post&#xD;
           cuff deflation relative to baseline will be indexed to the changes in the opposite arm&#xD;
           to give the reactive hyperaemia index. This measure of endothelial function constitutes&#xD;
           the outcome measure.&#xD;
&#xD;
        2. Blood Pressure Assessment Brachial artery blood pressure will be measured in the left&#xD;
           arm in the supine position using an automated device (Dinamap) and in accordance with&#xD;
           the clinical research facility SOP.&#xD;
&#xD;
        3. Blood samples and urine samples&#xD;
&#xD;
      Samples for plasma will be centrifuged and stored at -80C. Biochemical analysis will be&#xD;
      performed by the laboratory of the STH NHS Trust for standard tests and by validated assays&#xD;
      for non-routine markers (as detailed below) in the Academic Nephrology Unit.&#xD;
&#xD;
      Participants will be asked to collect a 24h urine sample from the day before the study visit&#xD;
      and to provide a spot urine sample on the day. This will be analysed at the laboratory of the&#xD;
      STH NHS Trust.&#xD;
&#xD;
      Biochemical Analysis&#xD;
&#xD;
      Serum samples will be analyzed for Full blood count, Urea, Electrolytes, Glucose, Insulin,&#xD;
      Lipid Profile, Homocysteine, (Hs) CRP and Creatinine Levels.&#xD;
&#xD;
      Serum and plasma will also be stored for future analysis of relevant biomarkers of&#xD;
      endothelial function or nitric oxide metabolism as indicated by preliminary results.&#xD;
&#xD;
      Urine samples will be analysed initially for protein creatinine ratio (PCR). The rest will be&#xD;
      frozen for future analysis of urinary biomarkers of endothelial function or nitric oxide&#xD;
      metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2011</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive hyperemia index (RHI)</measure>
    <time_frame>Baseline</time_frame>
    <description>EndoPAT values (Endoscore)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic Blood pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>Baseline</time_frame>
    <description>Protein creatinine ratio</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>ADPKD</arm_group_label>
    <description>ADPKD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Peripheral (digital) arterial tonometry</intervention_name>
    <description>This will be measured using the EndoPAT system (Itamar Medical)</description>
    <arm_group_label>ADPKD</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normotensive ADPKD patients with well preserved GFR (&gt;60ml/min) ie those with Stage 1 or 2&#xD;
        Chronic Kidney Disease recruited from a specialist PKD clinic. Healthy controls will be&#xD;
        recruited matched to age, sex, body mass index (BMI) and eGFR of the ADPKD patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18yrs, &lt;50yrs&#xD;
&#xD;
          -  Able to understand spoken/written English sufficiently to give informed consent and to&#xD;
             take part in clinical assessment&#xD;
&#xD;
          -  Clinical diagnosis of ADPKD&#xD;
&#xD;
          -  eGFR &gt;60ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of cardiovascular disease or hypertension&#xD;
&#xD;
          -  Not diabetic&#xD;
&#xD;
          -  Not smoking&#xD;
&#xD;
          -  Not breastfeeding&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Not taking any regular medication (except oral contraceptives)&#xD;
&#xD;
          -  No musculoskeletal conditions contraindicating inflation of a blood pressure cuff to&#xD;
             suprasystolic pressures around the forearm (as part of EndoPAT measurements)&#xD;
&#xD;
          -  Not morbidly obese: BMI&lt;35 (May contribute to endothelial dysfunction)&#xD;
&#xD;
          -  eGFR &lt;60ml/min/1.73m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Ong</last_name>
    <role>Principal Investigator</role>
    <affiliation>STH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Chico</last_name>
    <role>Study Director</role>
    <affiliation>STH</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

